Status:

COMPLETED

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Lead Sponsor:

Janssen Research & Development, LLC

Conditions:

Obesity

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tol...

Eligibility Criteria

Inclusion

  • Body mass index (BMI) greater than or equal to (\>=) 35 to less than or equal to (\<=) 50 kilogram per square meter (kg/m\^2) at the screening visit
  • Stable weight (that is, change of \<= 5 percent \[%\] within 12 weeks before screening based on medical history)
  • Women must be either: (a) Postmenopausal, or (b) Permanently sterilized or otherwise be incapable of pregnancy, or (c) Heterosexually active and practicing a highly effective method of birth control, or (d) Not heterosexually active
  • Woman of childbearing potential have a negative pregnancy test at screening
  • Willing and able to adhere to specific the prohibitions and restrictions

Exclusion

  • History of obesity with a known secondary cause (for example, Cushing's disease/syndrome)
  • History of Type 1 diabetes mellitus, Type 2 diabetes mellitus (T2DM), diabetic ketoacidosis (DKA), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
  • Has a Hemoglobin A1c (HbA1c) of \>= 6.5% or fasting plasma glucose (FPG) \>= 126 milligrams per deciliter (mg/dL) (\>= 7.0 millimoles per liter \[mmol/L\]) at screening
  • Screening calcitonin of \>= 50 picograms per milliliter (pg/mL) personal history or family history of medullary thyroid cancer, or of multiple endocrine neoplasia syndrome type 2 (MEN 2), regardless of time prior to screening
  • History of glucagonoma

Key Trial Info

Start Date :

March 26 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 8 2019

Estimated Enrollment :

474 Patients enrolled

Trial Details

Trial ID

NCT03486392

Start Date

March 26 2018

End Date

March 8 2019

Last Update

February 5 2020

Active Locations (51)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (51 locations)

1

Central Phoenix Medical Clinic

Phoenix, Arizona, United States, 85020

2

Diablo Clinical Research, Inc.

Walnut Creek, California, United States, 94598

3

Care Partners Clinical Research

Jacksonville, Florida, United States, 32277

4

Advanced Clinical Research

Boise, Idaho, United States, 83642